Sanofi SA (NASDAQ:SNY) and Johnson & Johnson (NYSE:JNJ) have discontinued the E.mbrace phase 3 study evaluating a vaccine ...

Fabry Disease Clinical Trial Pipeline Major pharmaceutical companies are working to advance the pipeline space and unlock the future growth ...

20% of bioreactor runs at the Genzyme facility failed due to contamination or quality issues over 2.5 years. FDA identified 84 overdue deviation investigations, some exceeding 180 days ...

Orchard Therapeutics has tasked Robin Kenselaar with accelerating growth of Lenmeldy, the world’s most expensive drug, ...

Q4 2024 Earnings Call Transcript February 12, 2025 Operator: Good morning. My name is Jennifer and I will be your conference ...

Topical steroid withdrawal syndrome may signal a reminder to clinicians to be good stewards of topical treatments, according ...

Through policy framework shifts, appeals to the court for rare disease funds, and starting a centre in Bengaluru, Prasanna ...

From diagnosis to treatment, a speaker at the Masters of Pediatric Dermatology conference discussed updates for treating vascular birth marks in infants.In an interview with Healio, Mercedes E.

Despite receiving a prior wrist slap from the FDA in the shape of a Form 483, Sanofi is still working to right the ship at a U.S. drug ingredients plant tied to its longstanding subsidiary Genzyme.

Seven rheumatology researchers have authored a paper questioning the utility of the 2024 National Academies’ broad definition of long COVID.

At this time, I'd like to welcome everyone to the Biogen fourth-quarter and full-year 2024 earnings call and business update. [Operator instructions] Today's conference is being recorded. Thank you. I ...

At this time, I'd like to welcome everyone to the Biogen fourth-quarter and full-year 2024 earnings call and business update. (Operator Instructions) Today's conference is being recorded. Thank you. I ...